~~<i id='90A8A935E5'><strike id='90A8A935E5'><tt id='90A8A935E5'><pre id='90A8A935E5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：explore 2025-09-03 03:17:51 - browse：3

A traditional Chinese medicine compound used for cardiac benefits might help reduce the incidence of major adverse cardiac and cerebrovascular events and even cardiac death rates, according to a new study published Tuesday in the Journal of the American Medical Association.

However, some outside experts expressed skepticism about the result.

Tongxinluo — which means “to open (tong) the network (luo) of the heart (xin)” in Mandarin — is a traditional Chinese medicine compound made out of a mixture of powders and extracts from plants, centipedes, cicadas, and other sources.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

leisure time

focus

knowledge

focus

entertainment

Foodmakersdon'twantregulatorstofocusonultra-processedfoodswhentheygotoupdatedietaryguidelines.DanKit

WSS

Immunocompromised patients offer clues on chronic Covid

Diverse clinical trials: Why aren’t we there yet?

A common UTI test for kids haunts adults as a traumatic 'nightmare'

The inclusion problem at the heart of rehabilitation research

Mass General, Mayo Clinic look to monetize custom

Will the IRA bring competition to the biologics market?

knowledge

explore

leisure time

Supreme Court strikes down use of affirmative action

Microsoft launches AI tool for clinical documentation through Epic

DIEP, the 'gold standard' of breast reconstruction, is under threat

Walmart eyes Medicare Advantage provider ChenMed

As demand for Covid shots wanes, Moderna seeks its next success

WATCH: Why do bright lights make us see spots?

State Dept. review finds Biden bears some blame for Afghanistan failures

PEPFAR is under serious threat — and so is global health

Trump demands the U.S. pay no more for drugs than other countries … again

How medical schools plan to diversify without affirmative action

focus

Hospitals consider fixing cancer drug shortages on their own

Long Covid needs a new name — and a new frame

Popular nasal decongestant doesn't actually relieve congestion

Will the IRA bring competition to the biologics market?

There's an unseen cost to disruptive road

How to make the FDA’s new prescription one

focus

knowledge

focus

entertainment